Tolinapant treatment has an immunomodulatory effect on human TCL patients. (A) Heatmap summarizing the cell type profiling scores for sets of paired PTCL biopsies from 6 patients (A-F), before (light gray) and after (dark gray) tolinapant treatment. Signature sets of gene expression associated with different cell types were scored with NanoString Advanced Analysis cell profiling module and converted to z scores. CD8 (B) and cytotoxic cells (C) scores, before vs after tolinapant treatment, in tumor biopsies of patients evaluated using NanoString Advanced Analysis modules. Responder patients are highlighted in red. All cell type scores are in log2 scale. Paired cell type scores were compared using a 2-sided Wilcoxon signed-rank test. Both P values are not significant when adjusted for multiple comparisons. (D) Volcano plot showing differentially expressed cytokines (highlighted in red circles) in plasma from patients upon treatment with tolinapant. Significant (FDR < 0.1) cytokines upregulated posttreatment are highlighted as yellow points. Horizontal red dashed line represents FDR < 0.05. (E) Log2 expression values of cytokines in plasma from 5 PTCL patients on days 1 and 8 of tolinapant cycle 1. Responder patients are highlighted in red.